A new meta-analysis of more than 6000 studies shows that oral contraceptives significantly reduce the risk of ovarian cancer. The risk reduction increases proportionally with duration of use.
See the abstract here
Related Topics
Action Alert: Support Gynecologic Cancer Initiatives for FY2027
On March 17, Ovarian Cancer Research Alliance (OCRA) Advocate Leaders from across the country will be on Capitol Hill for OCRA’s Spring Advocacy Day—and we need your voice, too. If you can’t join us in person, please take action to reinforce our efforts on the Hill and help us make a big impact. Advocacy Day Priorities This … Continued
OCRA’s Advocate’s Corner: February 2026
Written by Chad Ramsey, Vice President, Policy February brought meaningful progress in Washington. From major legislative wins to the start of a new appropriations cycle, advocates are already helping shape the policy landscape for ovarian and gynecologic cancer patients in 2026 and beyond. State-Level Momentum: Biomarker Progress Continues Momentum is building across the country to … Continued
Ovarian Cancer Research Alliance Honors Researchers with 2025 Rosalind Franklin and Schreiber Prizes
Recognizing Advances in Ovarian Cancer Research and Immunotherapy Ovarian Cancer Research Alliance (OCRA) announced today the winners of two prizes recognizing exceptional accomplishments in ovarian cancer research. David Huntsman, MD, FRCPC, FCCMG, was awarded the 2025 Rosalind Franklin Prize for Excellence in Ovarian Cancer Research for his findings that have profoundly impacted the treatment of … Continued